Blood eosinophils in COPD: are biologics for everyone?
Abstract
Background:: Type 2 (T2) biologics represent a promising treatment option for chronic obstructive pulmonary disease (COPD) patients with eosinophilic inflammation.
Objectives:: To evaluate the prevalence of stable COPD patients who may be eligible for T2 biologics.
Design:: Real-world, retrospective, monocentric study in COPD patients undergoing inpatient pulmonary rehabilitation.
Methods:: Clinical, functional, and inflammatory data were collected. Patients were considered eligible for T2 biologic therapy whether they were receiving optimized inhaled therapy and had a history of ⩾2 moderate and/or ⩾1 severe exacerbations in the previous year, together with a blood eosinophil count ⩾300 cells/μL.
Results:: Among 441 patients, 21.5% had blood eosinophil counts ⩾300 cells/μL and 6.8% fulfilled the combined eligibility criteria. A high burden of respiratory and cardiometabolic comorbidities and increased cardiovascular risk was observed in the overall population.
Conclusion:: Only a subgroup of patients seems eligible for biologics, treatment escalation should be based on optimized standard care management and patient phenotyping
Related
- Nationwide study of blood eosinophils in COPD: impact of exacerbations and corticosteroids
- Blood eosinophil count and intensive care unit admission in patients hospitalized for acute exacerbation of COPD: a retrospective cohort study.
- The Improving Access to Genetic Information for Everyone (IMAGINE) study: Protocol for a randomised controlled trial of a mainstreaming model of hereditary cancer multigene panel testing among patients of varying backgrounds
- Cadherin-related family member 3 upregulates the effector functions of eosinophils
- Is easy-to-read easy for everyone? An eye-tracking study across the adult lifespan.
BibTeX
@article{vanetti2026blood,
title = {{Blood eosinophils in COPD: are biologics for everyone?}},
author = {Marco Vanetti and Dina Visca and Francesco Ardesi and Antonia M. Taglioretti and Martina Zappa and Patrizia Pignatti and Antonio Spanevello},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2026},
month = sep,
doi = {10.1177/17534666261471839},
url = {https://doi.org/10.1177/17534666261471839},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Blood eosinophils in COPD: are biologics for everyone?
AU - Marco Vanetti
AU - Dina Visca
AU - Francesco Ardesi
AU - Antonia M. Taglioretti
AU - Martina Zappa
AU - Patrizia Pignatti
AU - Antonio Spanevello
PY - 2026
DA - 2026/09/19
JO - Therapeutic Advances in Respiratory Disease
DO - 10.1177/17534666261471839
UR - https://doi.org/10.1177/17534666261471839
AB - Background:: Type 2 (T2) biologics represent a promising treatment option for chronic obstructive pulmonary disease (COPD) patients with eosinophilic inflammation. Objectives:: To evaluate the prevalence of stable COPD patients who may be eligible for T2 biologics. Design:: Real-world, retrospective, monocentric study in COPD patients undergoing inpatient pulmonary rehabilitation. Methods:: Clinical, functional, and inflammatory data were collected. Patients were considered eligible for T2 biologic therapy whether they were receiving optimized inhaled therapy and had a history of ⩾2 moderate and/or ⩾1 severe exacerbations in the previous year, together with a blood eosinophil count ⩾300 cells/μL. Results:: Among 441 patients, 21.5% had blood eosinophil counts ⩾300 cells/μL and 6.8% fulfilled the combined eligibility criteria. A high burden of respiratory and cardiometabolic comorbidities and increased cardiovascular risk was observed in the overall population. Conclusion:: Only a subgroup of patients seems eligible for biologics, treatment escalation should be based on optimized standard care management and patient phenotyping
SN - 1753-4658
SN - 1753-4666
ER -